Susceptibility of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae According to the New CLSI Breakpoints
Authors:
- 1 September 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 49 (9) , 3127-3131
Abstract
In 2010 the Clinical and Laboratory Standards Institute (CLSI) lowered the susceptibility breakpoints of some cephalosporins and aztreonam for Enterobacteriaceae and eliminated the need to perform screening for extended-spectrum β-lactamases (ESBLs) and confirmatory tests. The aim of this study was to determine how many ESBL-producing strains of three common species of Enterobacteriaceae test susceptible using the new breakpoints. As determined with the CLSI screening and confirmatory tests, 382 consecutive ESBL-producing strains were collected at Huashan Hospital between 2007 and 2008, including 158 strains of Escherichia coli , 164 of Klebsiella pneumoniae , and 60 of Proteus mirabilis . Susceptibility was determined by the CLSI agar dilution method. CTX-M-, TEM-, and SHV-specific genes were determined by PCR amplification and sequencing. bla CTX-M genes alone or in combination with bla SHV were present in 92.7% (354/382) of these ESBL-producing strains. Forty-two (25.6%) strains of K. pneumoniae harbored SHV-type ESBLs alone or in combination. No TEM ESBLs were found. Utilizing the new breakpoints, all 382 strains were resistant to cefazolin, cefotaxime, and ceftriaxone, while 85.0 to 96.7% of P. mirabilis strains tested susceptible to ceftazidime, cefepime, and aztreonam, 41.8 to 45.6% of E. coli strains appeared to be susceptible to ceftazidime and cefepime, and 20.1% of K. pneumoniae were susceptible to cefepime. In conclusion, all ESBL-producing strains of Enterobacteriaceae would be reported to be resistant to cefazolin, cefotaxime, and ceftriaxone by using the new CLSI breakpoints, but a substantial number of ESBL-containing P. mirabilis and E. coli strains would be reported to be susceptible to ceftazidime, cefepime, and aztreonam, which is likely due to the high prevalence of CTX-M type ESBLs.Keywords
This publication has 28 references indexed in Scilit:
- Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infectionsInternational Journal of Antimicrobial Agents, 2011
- Positive Extended-Spectrum-β-Lactamase (ESBL) Screening Results May Be Due to AmpC β-Lactamases More Often than to ESBLsJournal of Clinical Microbiology, 2010
- AmpC β-LactamasesClinical Microbiology Reviews, 2009
- The continuing challenge of ESBLsCurrent Opinion in Pharmacology, 2007
- Spread of Extended-Spectrum β-Lactamase CTX-M-Producing Escherichia coli Clinical Isolates in Community and Nosocomial Environments in PortugalAntimicrobial Agents and Chemotherapy, 2007
- Molecular Epidemiology of CTX-M-Producing Escherichia coli in the Calgary Health Region: Emergence of CTX-M-15-Producing IsolatesAntimicrobial Agents and Chemotherapy, 2007
- Outcome of cephalosporin treatment of bacteremia due to CTX-M–type extended-spectrum β-lactamase–producing Escherichia coliDiagnostic Microbiology and Infectious Disease, 2006
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005
- Growing Group of Extended-Spectrum β-Lactamases: the CTX-M EnzymesAntimicrobial Agents and Chemotherapy, 2004
- Investigation of extended-spectrum β-lactamase in Klebsiellae pneumoniae and Escherichia coli from ChinaDiagnostic Microbiology and Infectious Disease, 2002